Moleculin Biotech Reports $7.6 Million Net Loss in Q2 2026, Focuses on Annamycin Trial

Moleculin Biotech, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $7.6 million, a decrease from the $17.8 million loss recorded in the same period of 2025. For the first half of 2026, the company reported a net loss of $20.5 million, compared to a loss of $23.7 million in the first half of 2025. The company did not generate any revenue during these periods, maintaining a consistent trend from previous quarters. Operating expenses for the second quarter increased to $7.6 million, up from $5.7 million in the prior year, primarily driven by higher research and development costs associated with ongoing clinical trials.

The company’s total assets decreased to $21.1 million as of June 30, 2026, down from $22.1 million at the end of 2025. Current assets also fell to $8.7 million, compared to $9.7 million at the end of the previous year. Current liabilities increased significantly to $9.3 million from $6.9 million, largely due to rising accounts payable and accrued expenses. The accumulated deficit reached $226.5 million, reflecting the ongoing financial challenges faced by the company as it continues to invest heavily in its clinical programs.

Moleculin has been actively engaged in its pivotal Phase 2/3 trial, known as the MIRACLE trial, evaluating its lead drug candidate Annamycin for the treatment of relapsed/refractory acute myeloid leukemia (AML). The company reported positive preliminary unblinded efficacy results from the first 45 patients enrolled in the trial, with complete remission rates significantly higher than the control arm. The trial is expected to conclude its first part by early 2027, with further data anticipated to provide insights into the drug's potential.

In terms of financing, Moleculin raised approximately $11.2 million through various equity offerings in the first half of 2026, although this was a decrease from $13.4 million raised in the same period of 2025. The company’s cash and cash equivalents stood at $7.3 million at the end of June 2026, which management indicated may not be sufficient to fund operations for the next year without additional financing. The company is exploring various funding options, including equity offerings and strategic partnerships, to support its ongoing clinical trials and operational needs.

Looking ahead, Moleculin remains focused on advancing its clinical programs, particularly Annamycin, while addressing its financial challenges. The company has indicated that it will require approximately $8 million in additional funding to sustain its operations into the second quarter of 2027. The successful completion of the MIRACLE trial and the potential commercialization of Annamycin could significantly impact the company's future financial performance and market position.